Incyte (INCY) return on equity (ROE)

Return on equity · fiscal 2025
24.9%

Incyte (INCY) earned a return on equity of 24.9% in fiscal 2025 (the year ended December 31, 2025). That is 24.0 percentage points higher than the 0.9% of fiscal 2024. Figures as of 17 Nov 2026, 22:49 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
24.9%
Change on fiscal 2024
+24.0 pts
Highest on record
25.2%fiscal 2021
Lowest on record
-19.2%fiscal 2017
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Incyte return on equity (ROE), in more detail

Across the 10 fiscal years on record (2016–2025), the highest was 25.2% in fiscal 2021 and the lowest -19.2% in fiscal 2017. The fiscal 2025 figure is higher than in 89% of the 9 earlier fiscal years on record, whose median is 7.8%.

History · 10 fiscal years

Return on equity by fiscal year

Incyte return on equity (ROE), year by year

Incyte (INCY) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202524.9% 24.0 pts up
20240.9% 10.6 pts down
202311.5% 3.7 pts up
20227.8% 17.4 pts down
202125.2% 36.5 pts up
2020-11.3% 28.5 pts down
201917.2% 11.5 pts up
20185.7% 24.9 pts up
2017-19.2% 44.1 pts down
201624.8%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Incyte and comparable companies
CompanyReturn on equityFiscal year
STERIS STE10.9%2026
Insmed INSM-172.8%2025
United Therapeutics UTHR18.8%2025
Incyte INCY24.9%2025
Viatris VTRS-23.9%2025
Tenet Healthcare THC33.3%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on INCY

Incyte, figure by figure

Incyte (INCY) overview: price, valuation and scorecardAll health care companies by market value

Incyte return on equity (ROE): questions and answers

What is Incyte's return on equity?

Incyte (INCY) earned a return on equity of 24.9% in fiscal 2025 (the year ended December 31, 2025). That is 24.0 percentage points higher than the 0.9% of fiscal 2024.

Is Incyte's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 89% of the 9 earlier fiscal years on record, whose median is 7.8%.

What are the highest and lowest return on equity figures on record for Incyte?

Across the 10 fiscal years on record (2016–2025), the highest was 25.2% in fiscal 2021 and the lowest -19.2% in fiscal 2017.

How is Incyte's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Incyte (INCY) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/INCY/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.